Landiolol: An Ultra-Short-Acting beta-Blocker.
Article Details
- CitationCopy to clipboard
Rao SJ, Kanwal A, Kanwal A, Danilov A, Frishman WH
Landiolol: An Ultra-Short-Acting beta-Blocker.
Cardiol Rev. 2024 Sep-Oct 01;32(5):468-472. doi: 10.1097/CRD.0000000000000555. Epub 2023 Apr 25.
- PubMed ID
- 37185629 [ View in PubMed]
- Abstract
Landiolol is an ultra-short-acting, highly cardio-selective, beta-blocker, that is currently approved for clinical use in Japan and the European Union, for the treatment of tachyarrhythmias. Landiolol is highly cardio-selective with high beta1 selectivity and receptor affinity, resulting in a more potent chronotropic effect and less potent hypotensive effect compared with other beta-blockers such as esmolol and propranolol. Based on the recent randomized controlled trials, low-dose landiolol may have a beneficial role in the prevention and management of postoperative atrial fibrillation following noncardiac and cardiac surgeries, including on-pump and off-pump coronary artery bypass grafting and valve surgery. Additionally, landiolol may have potential utility for myocardial salvage and prevention of postpercutaneous coronary intervention myocardial infarction. Furthermore, the use of landiolol may also have a therapeutic effect for rate control of sepsis-related tachyarrhythmias. Positive results of recent randomized controlled trials should continue to inspire clinicians to conduct further, larger studies, to find new potential clinical applications for this novel drug.